| [1] |
冠心病合理用药指南(第2版)[J]. 中国医学前沿杂志(电子版), 2018, 10(6):1-130.
|
| [2] |
胡盛寿, 高润霖, 刘力生, 等. 《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019, 34(3):209-220.
|
| [3] |
Jain P. Traditional and novel non-statin lipid-lowering drugs[J]. Indian Heart J, 2023, 76 Suppl 1(Suppl 1):S38-S43.
|
| [4] |
Norata GD, Tibolla G, Catapano AL. PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges[J]. Vascul Pharmacol, 2014, 62(2):103-111.
|
| [5] |
Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes[J]. NEngl J Med, 2016, 375(22):2144-2153.
|
| [6] |
Bergeron N, Phan BAP, Ding Y, et al. Proprotein convertase subtilisin/kexin type 9 inhibition: A new therapeutic mechanism for reducing cardiovascular disease risk[J]. Circulation, 2015, 132(17):1648-1666.
doi: 10.1161/CIRCULATIONAHA.115.016080
pmid: 26503748
|
| [7] |
Sabatine MS. PCSK9 inhibitors: Clinical evidence and implementation[J]. Nat Rev Cardiol, 2019, 16(3):155-165.
doi: 10.1038/s41569-018-0107-8
pmid: 30420622
|
| [8] |
Santos RD, Wiegman A, Caprio S, et al. Alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: A randomized clinical trial[J]. JAMA Pediatr, 2024, 178(3):283-293.
doi: 10.1001/jamapediatrics.2023.6477
pmid: 38315470
|
| [9] |
Iannuzzo G, Buonaiuto A, Calcaterra I, et al. Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: A single center real-world study[J]. Nutr Metab Cardiovasc Dis, 2022, 32(3):684-691.
doi: 10.1016/j.numecd.2021.10.025
pmid: 34991937
|
| [10] |
Kaplon H, Crescioli S, Chenoweth A, et al. Antibodies to watch in 2023[J]. MAbs, 2023, 15(1):2153410.
|
| [11] |
Li JJ. Tafolecimab, a novel member of PCSK9 monoclonal antibodies, is worth expecting in a Chinese population[J]. JACC Asia, 2023, 3(4):646.
|
| [12] |
Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9[J]. J Lipid Res, 2008, 49(2):394-398.
doi: 10.1194/jlr.M700437-JLR200
pmid: 18033751
|
| [13] |
Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes[J]. Cell Metab, 2014, 20(4):573-591.
doi: 10.1016/j.cmet.2014.08.005
pmid: 25242225
|
| [14] |
Xu M, Zhu X, Wu J, et al. PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: A randomized, double-blind, placebo-controlled phase 1b/2 study[J]. BMC Med, 2022, 20(1):1-13.
|
| [15] |
Raschi E, Casula M, Cicero AFG, et al. Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events[J]. Pharmacol Ther, 2023, 250:108507.
|
| [16] |
Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia[J]. N Engl J Med, 2020, 383(8):711-720.
|
| [17] |
Warden BA, Duell PB. Evinacumab for treatment of familial hypercholesterolemia[J]. Expert Rev Cardiovasc Ther, 2021, 19(8):739-751.
|
| [18] |
Wiegman A, Greber-Platzer S, Ali S, et al. Evinacumab for pediatric patients with homozygous familial hypercholesterolemia[J]. Circulation, 2024, 149(5):343-353.
|
| [19] |
Graham MJ, Lee RG, Brandt TA, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides[J]. N Engl J Med, 2017, 377(3):222-232.
|
| [20] |
Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia[J]. Eur Heart J, 2020, 41(40):3936-3945.
doi: 10.1093/eurheartj/ehaa689
pmid: 32860031
|
| [21] |
Pfizer. Pfizer and Ionis announce discontinuation of Vupanorsen clinical development program[EB/OL]. [2022-01-31].https://www.vbdata.cn/newsDetail/6a727552829011ec8b9100163e0cb09b.
|
| [22] |
Watts GF, Scott R, Gladding P, et al. RNA interference targeting hepatic angiopoietin-like protein 3 results in prolonged reductions in plasma triglycerides and LDL-C in human subjects[J]. Circulation, 2019, 140:E987-988.
|
| [23] |
Watts GF, Schwabe C, Scott R, et al. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: Phase 1 basket trial cohorts[J]. Nat Med, 2023, 29(9):2216-2223.
doi: 10.1038/s41591-023-02494-2
pmid: 37626170
|
| [24] |
Tomlinson B, Wu QY, Zhong YM, et al. Advances in dyslipidaemia treatments: Focusing on ApoC3 and ANGPTL3 inhibitors[J]. J Lipid Atheroscler, 2023, 13(1): 2-20.
|
| [25] |
Raal F, Bergeron J, Watts GF, et al. ARO-ANG3, an investigational RNAi therapeutic, decreases serum LDL-cholesterol, apolipoprotein B, and angiopoietin-like protein 3 in patients with homozygous familial hypercholesterolaemia[EB/OL]. [2023-06-18].https://xueshu.baidu.com/usercenter/paper/show?paperid=17490tb0t74f0t30jg0b08g014512614&site=xueshu_se.
|
| [26] |
Forcheron F, Cachefo A, Thevenon S, et al. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients[J]. Diabetes, 2002, 51:3486-3491.
pmid: 12453904
|
| [27] |
Crosby J, Peloso GM, Auer PL, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease[J]. N Engl J Med, 2014, 371:22-31.
|
| [28] |
Graham MJ, Lee RG, Bell TA 3rd, et al. Antisense oligonucleotide inhibition of apolipoprotein C-Ⅲ reduces plasma triglycerides in rodents, nonhuman primates, and humans[J]. Circ Res, 2013, 112:1479-1490.
|
| [29] |
Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-Ⅲ in patients with hypertriglyceridemia[J]. N Engl J Med, 2015, 373:438-447.
|
| [30] |
Prohaska TA, Alexander VJ, Karwatowska-Prokopczuk E, et al. APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia[J]. J Clin Lipidol, 2023, 17:406-411.
doi: 10.1016/j.jacl.2023.04.007
pmid: 37164837
|
| [31] |
Alexander VJ, Xia S, Hurh E, et al. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels[J]. Eur Heart J, 2019, 40:2785-2796.
doi: 10.1093/eurheartj/ehz209
pmid: 31329855
|
| [32] |
Tardif JC, Karwatowska-Prokopczuk E, Amour ES, et al. Apolipoprotein C-Ⅲ reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk[J]. Eur Heart J, 2022, 43:1401-1412.
|
| [33] |
Schwabe C, Scott R, Sullivan D, et al. RNA interference targeting apolipoprotein C-Ⅲ with ARO-APOC3 in healthy volunteers mimics lipid and lipoprotein findings seen in subjects with inherited apolipoprotein C-Ⅲ deficiency[J]. EUR HEART J, 2020, 41(Supple 2):3330.
|
)
